Size-exclusion chromatography: How to upgrade your current methods

Size-exclusion chromatography (SEC) is a well-established analytical method for quantitative and qualitative aggregate analysis of monoclonal antibodies (mAbs) and other related biotherapeutics. Developing a robust, transferable SEC method for routine testing can be challenging for many analytical development laboratories, and is becoming increasingly difficult for those wanting to consider different LC instrumentation, transition from a legacy SEC method, or for those wanting to define which method parameters will demonstrate robustness.

In this webinar, hear from Dr. Helen Whitby, senior product manager at Phenomenex, as she explores SEC method development, with a focus on method transfer and sustainability. U/HPLC system configurations, differences in SEC column chemistries, and experimental method parameters will also be explored to ensure the analytical method demonstrates robustness, which can be sustained to support the entirety of a biotherapeutic life cycle.

Key learning objectives

• Understand the impact of U/HPLC systems, including bio-inert and traditional stainless-steel configurations to obtain robust and reproducible aggregate analysis data via SEC
• Understand how to transition from a legacy SEC method to improve analytical method throughput and data quality
• Determine the experimental parameters to ensure demonstration of analytical method robustness

Presenter: Dr. Helen Whitby (Senior Product Manager – Bioseparations, Phenomenex)

Helen has a Ph.D. in synthetic, organic, and analytical chemistry from the University of Manchester, United Kingdom, and has worked at Phenomenex for the last 15 years specializing in HPLC and Bioseparations.

Presenter: Carrie Haslam (Associate Editor, SelectScience)

Dr. Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Materials Science, Alzheimer’s disease and Clinical Diagnostics.

Carrie completed a Ph.D. from The University of Plymouth, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.